Senores Pharmaceuticals Limited
Senores Pharma reported strong Q4 FY26 revenue of Rs.190 crore, up 66% YoY, and PAT of Rs.32 crore, up 78% YoY. Full-year FY26 revenue increased 62% to Rs.664 crore, with PAT doubling to Rs.122 crore. The company guides for 30-40% revenue growth and 50-60% PAT growth for FY27.
May 19 2026 17:05:00
Senores Pharmaceuticals Ltd - 544319 - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On March 31, 2026
Senores Pharma provided an update on the utilization of its Rs. 500 crore IPO funds. A Rs. 33.02 crore capex for its subsidiary, Havix, is delayed to FY27 due to geopolitical issues. Additionally, Rs. 6.31 crore from offer expenses and Rs. 0.40 crore from debt repayment were re-allocated to general corporate purposes and inorganic growth.
May 14 2026 15:05:00
Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Senores Pharmaceuticals' Q4 FY26 Monitoring Agency Report highlights delays in deploying IPO proceeds. Significant delays include Rs. 33.02 cr for a manufacturing facility, now extended to FY27, and working capital investments. Funds have been re-allocated between various objectives.
May 14 2026 15:05:00
Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Senores Pharmaceuticals released its Q4 and FY26 financial results via a media release, reporting strong performance. Q4 total income increased by 66% to Rs.190 crore and PAT rose 104% to Rs.37 crore. The company also announced strategic acquisitions of Zoraya and Apnar Pharmaceuticals, and a new joint venture in the U.S. Federal Market.
May 14 2026 14:05:00
Senores Pharmaceuticals Ltd - 544319 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 14, 2026
Senores Pharma announced strong Q4 FY26 and full-year FY26 consolidated financial results. Q4 total income grew 66% to ₹190 Cr, EBITDA surged 219% to ₹62 Cr, and PAT increased 104% to ₹37 Cr. The company completed 75% stake acquisition in Apnar Pharmaceuticals and formed a 70% JV, Amerisyn, for the US federal market.
May 14 2026 14:05:00
Senores Pharmaceuticals Ltd - 544319 - Board Meeting Intimation for Considering And Approving The Audited Consolidated And Standalone Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 And To Transact Other Business Matters
Senores Pharmaceuticals board is scheduled to meet on May 14, 2026. The primary agenda is to consider and approve the audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026.
May 08 2026 17:05:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals promoters and promoter group confirmed no new encumbrances on company shares during the financial year ended March 31, 2026. This annual disclosure ensures compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
Apr 22 2026 17:04:00
Read More
